Clinical trial NCT03053167 - References

ColoRectal Cancer — Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

Citation(s)

•   Aparicio J, de las Peñas R, Vicent JM, Garcerá S, Llorca C, Maestu I, Yuste AL, Farrés J
  Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Oncology. 2002;63(1):42-7.
•   Carnaghi C, Rimassa L, Garassino I, Zucali PA, Masci G, Fallini M, Morenghi E, Santoro A
  Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. Ann Oncol. 2002 Sep;13(9):1424-9.
•   Chiara S, Nobile MT, Tomasello L, Acquati M, Taveggia P, Murolo C, Percivale P, Rosso R
  Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer. Anticancer Res. 2005 Mar-Apr;25(2B):1391-6.
•   Feliu J, Salud A, Escudero P, López-Gómez L, Pericay C, Castañón C, de Tejada MR, Rodríguez-García JM, Martínez MP, Martín MS, Sánchez JJ, Barón MG; Oncopaz Cooperative Group and Associated Hospitals
  . Irinotecan plus raltitrexed as first-line treatment i

Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients: An Open-label, Single-arm, Multicenter Phase II Study

Details for clinical trial NCT03053167